Browse drugs

…ients reporting mild local injection site irritation.Conclusion Inclisiran significantly reduces LDL cholesterol levels, with the greatest…

…duction of 52% ±12 (95% CI) was found in those with statins and Inclisiran. For those intolerant of statins, use of Inclisiran led to a me…

…ee patients developed mild injection-site skin rash.Conclusions Inclisiran produced substantial and clinically meaningful reductions in LD…

… TA 733. Available from: https://www.nice.org.uk/guidance/ta733 Icosapent ethyl with statin therapy for reducing the risk of cardiovascular eve…

…isease, and three with familial hypercholesterolaemia. Prior to inclisiran, 11 patients (28.9%) had been treated with evolocumab and 2 pat…

…ed (75.96%) or familial hypercholesterolaemia were treated with inclisiran. The median baseline values of lipid parameters were: LDL 108.7…

… included (40% women; 60±7 years), all in secondary prevention. Inclisiran was indicated for failure to reach LDL-C targets despite optima…

…th the greatest reductions in LDL-C, followed by inclisiran and bempedoic acid.…

… therapies produce substantial reductions in Lp(a) levels, with Olpasiran demonstrating the greatest efficacy. Overall, these agents exhi…

…idaemia despite intensive treatment with statins and ezetimibe. Inclisiran, a small interfering ribonucleic acid that inhibits hepatic syn…

…itors (PCSK9 inhibitors), including evolocumab, alirocumab, and inclisiran, are potent lipid-lowering agents indicated for patients at hig…

… including alirocumab, bococizumab, evolocumab, tafolecimab and inclisiran. Eligible studies reported changes in LDL-C, apolipoprotein B (…